Cargando…

Differences in performance on English and Hebrew versions of the MoCA in Parkinson's patients()()

INTRODUCTION: The Montreal Cognitive Assessment (MoCA), an instrument widely used for cognitive screening in Parkinson's disease (PD), is validated in Hebrew and English. However, it remains unknown whether the scores are comparable. METHODS: The MoCA was analyzed in 483 Ashkenazi Jewish PD pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yaqian, Mirelman, Anat, Saunders-Pullman, Rachel, Mejia-Santana, Helen, Caccappolo, Elise, Raymond, Deborah, Giladi, Nir, Bressman, Susan, Marder, Karen, Alcalay, Roy N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8174235/
https://www.ncbi.nlm.nih.gov/pubmed/34095813
http://dx.doi.org/10.1016/j.prdoa.2020.100042
_version_ 1783702864207544320
author Xu, Yaqian
Mirelman, Anat
Saunders-Pullman, Rachel
Mejia-Santana, Helen
Caccappolo, Elise
Raymond, Deborah
Giladi, Nir
Bressman, Susan
Marder, Karen
Alcalay, Roy N.
author_facet Xu, Yaqian
Mirelman, Anat
Saunders-Pullman, Rachel
Mejia-Santana, Helen
Caccappolo, Elise
Raymond, Deborah
Giladi, Nir
Bressman, Susan
Marder, Karen
Alcalay, Roy N.
author_sort Xu, Yaqian
collection PubMed
description INTRODUCTION: The Montreal Cognitive Assessment (MoCA), an instrument widely used for cognitive screening in Parkinson's disease (PD), is validated in Hebrew and English. However, it remains unknown whether the scores are comparable. METHODS: The MoCA was analyzed in 483 Ashkenazi Jewish PD patients in Tel-Aviv and New York who had MoCA ≥21. Each section of the MoCA was compared between English and Hebrew. Linear regression models were used to test the association between MoCA performance and language. RESULTS: Total MoCA scores were lower in Hebrew than in English (25.4 versus 26.1; P = 0.007), even after adjustment for age, sex, PD duration, genotype, levodopa equivalent dose, the Unified Parkinson's Disease Rating Scale (UPDRS-III), and Geriatric Depression Scale score in a linear model (P < 0.001). However, when language sections were removed from the total, scores were similar between the languages (Hebrew 23.7 versus English 23.4, P = 0.111). CONCLUSION: The language section of the MoCA may be more difficult in Hebrew. The comparability of MoCA in different languages requires further evaluation.
format Online
Article
Text
id pubmed-8174235
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-81742352021-06-03 Differences in performance on English and Hebrew versions of the MoCA in Parkinson's patients()() Xu, Yaqian Mirelman, Anat Saunders-Pullman, Rachel Mejia-Santana, Helen Caccappolo, Elise Raymond, Deborah Giladi, Nir Bressman, Susan Marder, Karen Alcalay, Roy N. Clin Park Relat Disord Short Communication INTRODUCTION: The Montreal Cognitive Assessment (MoCA), an instrument widely used for cognitive screening in Parkinson's disease (PD), is validated in Hebrew and English. However, it remains unknown whether the scores are comparable. METHODS: The MoCA was analyzed in 483 Ashkenazi Jewish PD patients in Tel-Aviv and New York who had MoCA ≥21. Each section of the MoCA was compared between English and Hebrew. Linear regression models were used to test the association between MoCA performance and language. RESULTS: Total MoCA scores were lower in Hebrew than in English (25.4 versus 26.1; P = 0.007), even after adjustment for age, sex, PD duration, genotype, levodopa equivalent dose, the Unified Parkinson's Disease Rating Scale (UPDRS-III), and Geriatric Depression Scale score in a linear model (P < 0.001). However, when language sections were removed from the total, scores were similar between the languages (Hebrew 23.7 versus English 23.4, P = 0.111). CONCLUSION: The language section of the MoCA may be more difficult in Hebrew. The comparability of MoCA in different languages requires further evaluation. Elsevier 2020-02-11 /pmc/articles/PMC8174235/ /pubmed/34095813 http://dx.doi.org/10.1016/j.prdoa.2020.100042 Text en © 2020 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Short Communication
Xu, Yaqian
Mirelman, Anat
Saunders-Pullman, Rachel
Mejia-Santana, Helen
Caccappolo, Elise
Raymond, Deborah
Giladi, Nir
Bressman, Susan
Marder, Karen
Alcalay, Roy N.
Differences in performance on English and Hebrew versions of the MoCA in Parkinson's patients()()
title Differences in performance on English and Hebrew versions of the MoCA in Parkinson's patients()()
title_full Differences in performance on English and Hebrew versions of the MoCA in Parkinson's patients()()
title_fullStr Differences in performance on English and Hebrew versions of the MoCA in Parkinson's patients()()
title_full_unstemmed Differences in performance on English and Hebrew versions of the MoCA in Parkinson's patients()()
title_short Differences in performance on English and Hebrew versions of the MoCA in Parkinson's patients()()
title_sort differences in performance on english and hebrew versions of the moca in parkinson's patients()()
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8174235/
https://www.ncbi.nlm.nih.gov/pubmed/34095813
http://dx.doi.org/10.1016/j.prdoa.2020.100042
work_keys_str_mv AT xuyaqian differencesinperformanceonenglishandhebrewversionsofthemocainparkinsonspatients
AT mirelmananat differencesinperformanceonenglishandhebrewversionsofthemocainparkinsonspatients
AT saunderspullmanrachel differencesinperformanceonenglishandhebrewversionsofthemocainparkinsonspatients
AT mejiasantanahelen differencesinperformanceonenglishandhebrewversionsofthemocainparkinsonspatients
AT caccappoloelise differencesinperformanceonenglishandhebrewversionsofthemocainparkinsonspatients
AT raymonddeborah differencesinperformanceonenglishandhebrewversionsofthemocainparkinsonspatients
AT giladinir differencesinperformanceonenglishandhebrewversionsofthemocainparkinsonspatients
AT bressmansusan differencesinperformanceonenglishandhebrewversionsofthemocainparkinsonspatients
AT marderkaren differencesinperformanceonenglishandhebrewversionsofthemocainparkinsonspatients
AT alcalayroyn differencesinperformanceonenglishandhebrewversionsofthemocainparkinsonspatients